Pro-inflammatory CXCL-10, TNF-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection
Anuradha S. Tripathy,Siddhesh Vishwakarma,Diptee Trimbake,Yogesh K. Gurav,Varsha Potdar,Nitin D Mokashi,Sudhir D Patsute,Himanshu Kaushal,Manohar Lal Choudhary,Bipin N Tilekar,Prakash Sarje,Varsha S Dange,Priya Abraham +12 more
Reads0
Chats0
TLDR
In this article, the authors investigated plasma cytokine and chemokine levels of 27 analytes from SARS-CoV-2-infected patients (in the early phase of infection), recovered individuals (45-60 days postinfection) and uninfected controls (n = 36) from the city of Pune located in the state of Maharashtra in India.Abstract:
Currently, the world is witnessing the pandemic of COVID-19, a disease caused by the novel coronavirus SARS-CoV-2. Reported differences in clinical manifestations and outcomes in SARS-CoV-2 infection could be attributed to factors such as virus replication, infiltration of inflammatory cells, and altered cytokine production. Virus-induced aberrant and excessive cytokine production has been linked to the morbidity and mortality of several viral infections. Using a Luminex platform, we investigated plasma cytokine and chemokine levels of 27 analytes from hospitalized asymptomatic (n = 39) and mildly symptomatic (n = 35) SARS-CoV-2-infected patients (in the early phase of infection), recovered individuals (45-60 days postinfection) (n = 40), and uninfected controls (n = 36) from the city of Pune located in the state of Maharashtra in India. Levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and the chemokine CXCL-10 were significantly higher, while those of the antiviral cytokines IFN-γ and IL-12 p70 were significantly lower in both asymptomatic and mildly symptomatic patients than in controls. Comparison among the patient categories revealed no difference in the levels of the cytokines/chemokines except for CXCL-10 being significantly higher and IL-17, IL-4, and VEGF being significantly lower in the mildly symptomatic patients. Interestingly, levels of all key analytes were significantly lower in recovered individuals than in those in both patient categories. Nevertheless, the level of CXCL10 was significantly higher in the recovered patients than in the controls, indicating that the immune system of SARS-CoV-2 patients may take a longer time to normalize. Our data suggest that IL-6, IL-1β, TNF-α, CXCL-10, and reduced antiviral cytokines could be used as biomarkers of SARS-CoV-2 infection.read more
Citations
More filters
Journal ArticleDOI
What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection?
TL;DR: The potential role of CXCL10 in the pathogenesis of COVID-19, as well as its potential immune–therapeutic significance, is described.
Journal ArticleDOI
Prognostic Markers in Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein
Manuela Rizzi,Martina Costanzo,Stelvio Tonello,Erica Matino,Francesco G. Casciaro,Alessandro Croce,Eleonora Rizzi,Erika Zecca,Anita R. Pedrinelli,Veronica Vassia,Raffaella Landi,Mattia Bellan,Luigi Mario Castello,Rosalba Minisini,Venkata Ramana Mallela,Gian Carlo Avanzi,Mario Pirisi,Daniele Lilleri,Pier Paolo Sainaghi +18 more
TL;DR: B baseline IP-10 and CRP after 7 days of hospitalization could be useful in driving clinical decisions tailored to the expected disease trajectory in hospitalized COVID-19 patients.
Journal ArticleDOI
Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion.
Marco Poeta,Valentina Cioffi,Vittoria Buccigrossi,Merlin Nanayakkara,Melissa Baggieri,Roberto Peltrini,Angela Amoresano,Fabio Magurano,Alfredo Guarino +8 more
TL;DR: In this paper, an aluminomagnesium silicate adsorbent clay with antidiarrheal effects was tested in Caco-2 cells using spike protein receptor-binding domain (RBD) and heat-inactivated SARS-CoV-2 preparations.
Journal ArticleDOI
Plasma biomarkers for systemic inflammation in COVID‐19 survivors
Juanzho Zhao,Madison Schank,Lingyu Wang,Xindi Dang,Dechao Cao,Sushant Khanal,Lam Ngoc Thao Nguyen,Y. Zhang,Xiao Y. Wu,James Adkins,Benjamin J Pelton,Jinyu Zhang,Shunbin Ning,Mohamed El Gazzar,Jonathan P. Moorman,Zhi Q. Yao +15 more
TL;DR: The aim of this study is to determine whether inflammatory proteins are dysregulated and can serve as potential biomarkers for systemic inflammation in COVID‐19 survivors.
Journal ArticleDOI
Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
Jaime Bravo Silva,Felipe Patricio,Aleidy Patricio-Martínez,Gerardo Santos-López,Lilia Cedillo,Yousef Tizabi,Ilhuicamina Daniel Limón +6 more
TL;DR: It is argued that SARS-Cov-2-induced cytokine storm, neuroinflammation and oxidative stress increase the risk of developing neurodegenerative diseases such as Alzheimer’s disease and Parkinson's disease.
References
More filters
Journal ArticleDOI
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.
Quanxin Long,Xiaojun Tang,Qiu Lin Shi,Qin Li,Hai Jun Deng,Jun Yuan,Jie Li Hu,Wei Xu,Yong Zhang,Fa Jin Lv,Kun Su,Fan Zhang,Jiang Gong,Bo Wu,Xia Mao Liu,Jin Jing Li,Jing Fu Qiu,Juan Chen,Ailong Huang +18 more
TL;DR: A cohort of asymptomatic patients infected with SARS-CoV-2 had significantly lower levels of virus-specific IgG antibodies compared to a cohort of age- and sex-matched symptomatic infected patients.
Journal ArticleDOI
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
TL;DR: Tocilizumab is a blocker of IL-6R, which can effectively block IL- 6 signal transduction pathway, and is likely to become an effective drug for patients with severe COVID-19.
Journal ArticleDOI
Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
Chun K. Wong,C. W. K. Lam,A. K. L. Wu,W. K. Ip,Nelson Lee,I. H. S. Chan,Lydia C.W. Lit,David S.C. Hui,M. H. M. Chan,S. S. C. Chung,Joseph J.Y. Sung +10 more
TL;DR: Together, the elevation of Th1 cytokine IFN‐γ, inflammatory cytokine IL‐1, IL‐6 and IL‐12 and chemokines IL‐8, MCP‐1 and IP‐10 confirmed the activation of Th 1 cell‐mediated immunity and hyperinnate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils.
Journal ArticleDOI
The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
TL;DR: This review will be aimed at providing an overview of the current knowledge on the involvement of the chemokine/chemokine-receptor system in the cytokine storm related to SARS-CoV-2 infection.
Journal ArticleDOI
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
TL;DR: IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.
Related Papers (5)
Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding.
Nadine Peart Akindele,Theodore Kouo,Andrew H. Karaba,Oren Gordon,Katherine Z.J. Fenstermacher,Jeanette Beaudry,Jessica H. Rubens,Christine C. Atik,Weiqiang Zhou,Hongkai Ji,Xueting Tao,Dhananjay Vaidya,Heba H. Mostafa,Patrizio Caturegli,Paul W Blair,Lauren Sauer,Andrea L. Cox,Deborah Persaud,Deborah Persaud +18 more